Atrium Medical: Repeated Inspection Findings and the Plant-Shutdown Decree

The Atrium Medical consent decree required a $6 million payment to the United States and shut Atrium’s Hudson, New Hampshire manufacturing plant, with limited exceptions, after the government alleged repeated quality system and medical device reporting failures. The government alleged that the Food and Drug Administration had found similar problems after earlier inspections and promises to correct them. For someone who knows the production line, the complaint files or the responses sent to FDA, this case shows how the distance between a promised correction and a working one can become the reason a plant stops shipping.

The Department of Justice announced the decree on February 3, 2015. Atrium manufactured chest drains, surgical meshes, vascular grafts and stent systems. The government brought the action at the Food and Drug Administration’s request to stop distribution of devices made under deficient controls and devices with missing required reports.

Repeated Inspection Findings and Promised Corrections

The government’s complaint traced recurring problems through Atrium inspections in March 2009, March 2010, September 2012 and 2013. The repeated subjects were process validation, corrective and preventive action, and device acceptance. These were the controls used to establish that a process worked, respond when something went wrong and decide whether finished devices could leave the plant.

According to the complaint, Food and Drug Administration investigators gave Atrium written observations after each inspection and discussed them with company representatives, who promised corrections each time. An October 2012 warning letter again raised process validation, corrective action and complaint handling. The government alleged similar violations when inspectors returned the following year. The promises kept coming. So did the inspection findings.

The complaint said Atrium responded in writing after that inspection and sent follow-up accounts of how and when it had made the promised changes. The government said those responses failed to address all the violations adequately.

A quality employee could recognize both sides of that comparison: what the response said had changed and what the production process actually did afterward.

Quality Controls and Overdue Device Reports

The 2013 allegations followed the device from production through release, then followed information about possible harm back into the company.

On the production side, the government alleged that Atrium failed to use established procedures to validate a process whose results could not be fully checked by later inspection and testing. It also alleged inadequate procedures to monitor and control a validated process. When the finished-device test cannot establish everything the process needed to get right, the validation and process records carry evidence the final test cannot supply.

At release, the government alleged inadequate procedures for accepting finished devices. In the corrective-action system, it alleged a failure to establish and maintain the procedures for addressing problems and preventing them from recurring.

The reporting allegation reached beyond the factory. The complaint said Atrium failed to submit a medical device report within 30 days of learning information reasonably suggesting that a marketed device may have caused or contributed to a death or serious injury. Information about possible patient harm had reached the manufacturer, according to the government, but the required report had not reached the Food and Drug Administration on time.

Injury reports from health care facilities and malfunction reports from importers flow to manufacturers, putting company complaint review at the center of what reaches the regulator.

Maquet’s Other Plants Drew Similar Allegations

The complaint also alleged quality-control failures at Maquet plants in Wayne, New Jersey, and Hechingen and Rastatt, Germany. At Hechingen, the government alleged failure to report a malfunction that would be likely to cause death or serious injury if it happened again. The reporting decision turned on the risk of recurrence.

Maquet managed quality operations across the companies. The complaint named its chief executive and managing director, who oversaw manufacturing and quality operations, and its corporate quality and compliance officer, who was responsible for quality compliance at the plants, as defendants.

What the Hudson Shutdown Changed

The decree required the Hudson manufacturing facility to shut down until the specified corrective work was complete. The Justice Department’s account of the order says that work included addressing deficiencies the Food and Drug Administration had already identified. Correction became a condition of operating the plant.

The decree allowed continued manufacture and distribution of certain devices deemed medically necessary, subject to notification and other requirements. That exception kept a controlled supply channel open while the plant faced correction requirements. For a manufacturing or distribution insider, the important connection is between the device being shipped and the permission under which that shipment continued.

From Device Failures to False Claims for Payment

The Atrium payment accompanied a court order to correct manufacturing and reporting failures. A healthcare whistleblower case follows the device into care billed to a government program. Medicare ordinarily pays the hospital or surgery center through a bundled payment that includes the implant. The purchase invoice and the claim for the patient’s care sit at different points in the transaction.

The 2020 Journal of Forensic and Investigative Accounting review A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud explains how a request for government payment can misrepresent the goods or services supplied, including by concealing facts that matter to the payment decision. For a device insider, the connection runs from what the company knew about its product to what the hospital billed Medicare for. Our whistleblower experts examine that connection with you.

St. Jude Medical’s 2021 civil settlement shows why internal device information can matter in that separate inquiry. The company agreed to pay $27 million over allegations that it sold defective implantable heart devices. The government alleged that St. Jude knew of serious injuries and a death associated with premature battery depletion when it told the Food and Drug Administration that none had been reported. The Justice Department said the withheld information would have led to a recall. That puts the complaint files in a different light: they can show what the company knew while its devices remained in use.

What an Insider Can See Across the Files

The Atrium complaint connects inspection observations, company responses, production controls and reporting decisions. A quality specialist may know whether a promised process change reached the production line. A complaint reviewer may know when information about an injury arrived and how the company evaluated it. A distribution employee may know which devices continued to ship under the medical necessity exception.

Those perspectives become more useful together. A response letter states what the company told FDA it had done. Validation and acceptance records concern the work inside the plant. Complaint and reporting files concern what the company learned after devices reached users. We work with insiders to understand where those accounts agree and where they diverge.

For an insider whose information also reaches false government payments, a whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We assess that payment connection with you and bring in medical device fraud whistleblower lawyers with experience in the conduct your records show.

You Know Whether the Correction Reached the Floor

If you saw a promised correction fail to reach production, or information about patient harm disappear between complaint review and reporting, speak to one of our Whistleblower Experts about what you saw. We connect your knowledge of the device business to any government payments it touched, build your strongest medical device whistleblower case with the right medical device fraud whistleblower lawyers and stay beside you throughout.